Key message: Inhaled corticosteroid therapy (ICS) reduces hospital admissions in patients with acute asthma who are not treated with oral or intravenous corticosteroids. It is unclear whether ICS reduces admissions in those given systemic corticosteroids and whether it could be used in place of systemic corticosteroids.
There are a range of options for the treatment of acute asthma but it is usual for early treatment to include giving corticosteroids orally or intravenously. The use of inhaled corticosteroids in this setting is less common. The Cochrane Airways Group has now updated its review investigating this treatment option, adding 16 randomized controlled trials (RCTs) with 1173 people, bringing the total to 32 trials with 2374 people. The results of 20 RCTs with 1405 people were combined.
What did they find?
- Compared to placebo, ICS given in the Emergency Department had a significant benefit in reducing hospital admission. With an admission rate of around 32% in the placebo group, about eight patients would need ICS treatment to prevent one admission
- ICS therapy was also associated with reduced hospital admission when all patients were given systemic corticosteroid treatment as well, but the most recent evidence is conflicting
- ICS appear to reduce hospital admissions in both children and adults
- Reductions in hospital admissions were similar for adults and children, for high and low doses of ICS and for different methods of ICS delivery
- ICS showed small beneficial effects on tests of lung function and it is unclear if these were clinically meaningful
- There was limited evidence on side effects but ICS appeared to be well tolerated
How good is the evidence?
Overall the evidence was judged to be of moderate quality.
It remains unclear whether ICS could be used in place of systemic corticosteroids in the Emergency Department treatment of acute asthma and questions remain about the most appropriate dosage and delivery device.
New evidence on other treatment options for acute asthma
The Cochrane Airways Group has also recently updated a review on the effectiveness of inhaled magnesium sulfate for acute asthma. This includes 16 RCTs with nearly 900 people. It’s disappointing that the evidence was not high quality, with all studies at a high or unclear risk of bias. It remains unclear whether magnesium sulfate improves lung function and reduces hospital admission, though indicators that it may be helpful for those with severe exacerbations of asthma warrant future study, the authors suggest.
A new Cochrane review on the addition of intravenous beta-agonists to inhaled beta-agonists for acute asthma was limited by the very small body of evidence on this topic, three trials with 104 people, so the value of this treatment option has yet to be established.
Another new Cochrane review compared intravenous beta-agonists with intravenous aminophylline for acute asthma and included eleven RCTs with 350 people. There was no consistent evidence favouring either approach, though side effects were fewer in people receiving beta-agonists, but the authors note that the results should be interpreted with caution given the small numbers of trials and patients.
An update to the Cochrane review on the use of non-invasive positive pressure ventilation for the treatment of respiratory failure caused by severe exacerbations of asthma highlighted the paucity of evidence available to guide clinicians about its use. Five RCTs with 206 patients were included, all judged to be low or very low quality and at high or unclear risk of bias.
These reviews add to a large collection of Cochrane reviews on asthma which have been gathered together on the Cochrane summaries website here
There’s also a special collection of Cochrane asthma reviews in the Cochrane Library highlighting a recent World Asthma Day here
You can also find a link to the latest version of the British Guideline on the Management of Asthma in the list below, which has cited evidence from 53 Cochrane reviews.
Edmonds ML, Milan SJ, Camargo Jr CA, Pollack CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD002308. DOI: 10.1002/14651858.CD002308.pub2. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002308.pub2/abstract
Powell C, Dwan K, Milan SJ, Beasley R, Hughes R, Knopp-Sihota JA, Rowe BH. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD003898. DOI: 10.1002/14651858.CD003898.pub5. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003898.pub5/abstract
Travers AH, Milan SJ, Jones AP, Camargo Jr CA, Rowe BH. Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD010179. DOI: 10.1002/14651858.CD010179 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010179/abstract
Travers AH, Jones AP, Camargo Jr CA, Milan SJ, Rowe BH. Intravenous beta2-agonists versus intravenous aminophylline for acute asthma. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD010256. DOI: 10.1002/14651858.CD010256. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010256/abstract
Lim WJ, Mohammed Akram R, Carson KV, Mysore S, Labiszewski NA, Wedzicha JA, Rowe BH, Smith BJ. Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD004360. DOI: 10.1002/14651858.CD004360.pub4.http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004360.pub4/abstract
Scottish Intercollegiate Guidelines Network (SIGN) and British Thoracic Society. British Guideline on the Management of Asthma. Edinburgh: SIGN; 2008. (SIGN publication no. 101). [May 2008, revised January 2012]. Available from URL: http://www.sign.ac.uk/pdf/sign101.pdf